22nd Century Group, Inc. is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing and modern plant breeding. Our primary mission in tobacco is to reduce the harm caused by smoking by bringing our proprietary reduced nicotine content tobacco cigarettes – containing 95% less nicotine than conventional cigarettes – to adult smokers in the U.S. and international markets. Our primary mission in hemp/cannabis is to develop proprietary hemp/cannabis plants with valuable cannabinoid profiles and agronomic traits and to commercialize those plants through a synergistic portfolio of strategic partnerships in the hemp/cannabis industry.
22nd Century Group, Inc.
500 Seneca Street, Suite 507
Buffalo, NY 14204
T: 716-270-1523
Contact Us
Mei Kuo
22nd Century Group, Inc.
Director, Communications & Investor Relations
500 Seneca Street, Suite 507
Buffalo, NY 14204
T: 716-300-1221
investorrelations@xxiicentury.com
Continental Stock and Transfer Company
1 State Street, 30th Floor
New York, NY 10004
T: 212-509-4000
cstmail@continentalstock.com